OBJECTIVE: To evaluate the role of clinical exchange programs in postgraduate obgyn training using the International Federation of Gynecology and Obstetrics (FIGO)-World Association of Trainees in Obstetrics and Gynecology (WATOG) One World Exchange (OWE), a clinical exchange program held in France in October 2023, as a case-study. METHODS: This was a cross-sectional study. A 31-item structured questionnaire designed with Google Forms was electronically distributed to the 51 obgyn postgraduate trainees (OWE fellows) who participated in the OWE, to collect information about the exchange. Collected data was analyzed using IBM Statistical Product and Service Solutions (SPSS) Statistics for Windows. RESULTS: The survey response rate was 68.6%. The mean age of the respondents was 33.0 ± 4.0 years. Majority of the them were females (26, 74.3%), married (19, 54.3%), at least in their third year of training (30, 85.7%) and from Africa (11, 31.4%). During the period of the exchange program, fellows observed various obstetric and gynecologic procedures, including open and minimal access procedures, with more than one-fifth (8, 22.9%) of them reporting that they were allowed to assist in some of these procedures. The fellows noted salient differences in practice between their exchange hospitals and their home countries. An overwhelming majority (30, 85.7%) of the fellows believed the OWE was beneficial and would positively impact their clinical practices back in their home countries. CONCLUSION: Clinical exchange programs like the OWE provide valuable benefits in improving the clinical knowledge and skills of postgraduate obgyn trainees.

• MeSH
• dospělí MeSH
• gynekologie * výchova   MeSH
• lidé MeSH
• mezinárodní vzdělávací výměna * MeSH
• porodnictví * výchova   MeSH
• průřezové studie MeSH
• průzkumy a dotazníky MeSH
• společnosti lékařské MeSH
• studium lékařství specializační postgraduální * metody   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Francie MeSH

Úvod: U idiopatické retroperitoneální fibrózy dominuje zavzetí ureterů do retroperitoneální fibrotické masy (zejména ve střední části ureterů), což vede k rozvoji (dolicho-) megaureterů s následnou progredující renální insuficiencí. Levá strana bývá postižena dříve. Řešením je ovlivnění etiopatogeneze onemocnění (zejména kortikoidní léčba) a derivace horních cest močových. Je možné provést buď trvalý stenting obou ureterů se všemi svými nevýhodami, či jejich deliberaci, která se historicky prováděla otevřeně ze střední laparotomie, nověji miniinvazivně. V práci hodnotíme výsledky miniinvazivní (laparoskopické, resp. roboticky asistované) deliberace a prezentujeme video robotické varianty. Soubor: V období 2001–2024 bylo k oboustranné deliberaci indikováno devět nemocných – tři muži (33 %) a šest žen; průměrný věk 58,5 ± 6,9 (48,8–69,6) roků; body mass index (BMI) 28,9 ± 5,8 (19,5–38,1). První čtyři řešení laparoskopicky, pět poté roboticky asistovaně. U dvou (22,2 %) nemocných nebylo možno uretery z těžkých fibrotických změn uvolnit (jeden z laparoskopie ponechán na stentech, druhý řešený roboticky asistovaně, provedena otevřená nefrektomie u ledviny s 8,6 % funkce a otevřená druhostranná deliberace – ze střední laparotomie). Doba operace obou stran (bez otevřeného výkonu) byla 154,0 ± 33,5 (100–201) min. Video: Ukazuje deliberaci obou ureterů roboticky asistovaně. Je užit čtyřramenný systém da Vinci Xi, poloha na boku 70°. Začínáme postiženější levou stranou. S Veres jehlou vytvořeno kapnoperitoneum tlakem 12 mm Hg, pupkem zaveden asistentský port 11 mm, za kontroly zraku zavedeny čtyři robotické 8mm porty. Kamera 30°, ProGraspTM, bipolární grasper MarylandTM, monopolární nůžky. Otevřeno parakolicky peritoneum, nalezen ureter a deliberován od dolního pólu ledviny až pod ilické cévy. Pod deliberovaný močovod vloženo mediální peritoneum a fixováno k laterálnímu okraji stehem či Hem-o-lok® L klipy. Ponechán port v pupku, změněna poloha a identicky proveden výkon i vpravo. Dutina břišní nedrénována. Ureterální stenty odstraněny za 3–6 týdnů. Výsledky: U 8 nemocných, kde bylo možno uretery deliberovat (15 močovodů, z toho 1 otevřeně), je známo dlouhodobé sledování všech 15 močovodů, u nich není nutný další stenting ureterů, horní cesty močové jsou sonograficky bez dilatace a nedochází k rozvoji renální insuficience. Doba sledování je v průměru 63,9 ± 64,3 (1–158) měsíců. U 8 kombinováno s kortikoidní terapií, která vedla vždy k výrazné regresi fibrotických hmot. Závěr: Deliberace močovodů při morbus Ormond je proveditelná miniinvazivně (laparoskopicky či roboticky asistovaně) u 77,8 % s překvapivě dobrými dlouhodobými výsledky umožňujícími uchránit horní cesty močové a vyhnout se dlouhodobému stentingu (ve 100 %). Robotické variantě dáváme nyní jednoznačně přednost.

Introduction: In idiopathic retroperitoneal fibrosis, ureteral involvement of the retroperitoneal fibrotic mass (especially in the middle part of the ureters) dominates, leading to the development of (dolicho-) megaureters with subsequent progressive renal insufficiency. The left side tends to be affected earlier. The solution is to influence the etiopathogenesis of the disease (especially corticoid treatment) and diversion of the upper urinary tract. Either permanent stenting of both ureters with all its disadvantages or ureterolysis. Historically open via midline laparotomy, more recently minimally invasive. In this paper we evaluate the results of minimally invasive (laparoscopic or robotic assisted) ureterolysis. Abstract: Between 2001 and 2024, nine patients were indicated for bilateral ureterolysis. Three men (33%) and six women. Mean age 58.5±6.9 (48.8-69.6) years. Body mass index (BMI) 28.9±5.8 (19.5-38.1). First four laparoscopically, subsequent five robotic assisted. In two (22.2%) patients ureters could not be released from severe fibrotic changes (one laparoscopy left with stents, the other robotically assisted open nephrectomy in a kidney with 8.6% function and open secondary ureterolysis - via midline laparotomy). The bilateral operation time (without open surgery) was 154.0±33.5 (100-201) min. Video: Shows the robotic-assisted bilateral ureterolysis. The 4-arm daVinci Xi system is used, 70° lateral position. Starting with the more affected left side. With Veres needle, capnoperitonum pressure of 12 mmHg created, 11 mm assisted port inserted through umbilicus, four robotic 8mm introduced under visual control. Camera 30°, ProGraspTM, bipolar grasper MarylandTM, monopolar scissors. Paracolic peritoneum opened, ureter found and liberated from the lower pole of the kidney to below the iliac vessels. Medial peritoneum inserted under the deliberated ureter and fixed to the lateral margin with suture or Hem-o-lok® L clips. The port in the umbilicus was left, the position was changed and the procedure was performed identically on the right side. The abdominal cavity was not drained. Ureteral stents removed in 3-6 weeks. Results: In the eight patients where ureters could be liberated (15 ureters, 1 open), long-term follow-up is known for all 15 ureters, no further ureteral stenting is required, the upper urinary tract is sonographically free of dilatation and no renal insufficiency developed. The mean follow-up time is 63.9±64.3 (1-158) months. In eight cases, combined corticosteroid therapy always resulted in significant regression of fibrotic masses. Conclusion: Liberation of ureters in morbus Ormond is feasible minimally invasively (laparoscopically or robotically assisted) in 77.8% with surprisingly good long-term results allowing preservation of the upper urinary tract and avoiding long-term stenting (in 100%). The robotic option is now clearly preferred.

• MeSH
• lidé MeSH
• miniinvazivní chirurgické výkony MeSH
• obstrukce močovodu chirurgie   MeSH
• retroperitoneální fibróza * komplikace   MeSH
• roboticky asistované výkony MeSH
• urologické chirurgické výkony MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• audiovizuální média MeSH

Úvod: Analýza tělesného složení pomocí ct vyšetření se v současnosti ukazuje jako významný prognostický nástroj u pacientů s indikací k transkatétrové implantaci aortální chlopně (tAVi). Její rutinní využití v klinické praxi je však limitováno složitostí dostupného softwaru a vysokými technickými nároky. naším cílem bylo vyvinout a validovat webovou aplikaci, která by zjednodušila používání existujícího softwaru AutoMAticA při hodnocení tělesného složení v rámci předintervenčního vyšetření před tAVi. Metody: Vyvinuli jsme webové rozhraní integrující již validovaný software AutoMAticA, který využívá umělou inteligenci pro automatickou segmentaci tkání. Systém analyzuje předintervenční ct snímky a auto- maticky vypočítává index kosterního svalstva, objem viscerálního a podkožního tuku. Aplikace zpracovává soubory DicoM a generuje přehledné reporty včetně segmentovaných snímků a kvantitativních parametrů. Výsledky: testování systému prokázalo průměrnou dobu analýzy 21 sekund od nahrání snímků po zobrazení výsledků. uživatelské hodnocení pěti klinickými lékaři potvrdilo jednoduchost použití a klinickou využitel- nost. Analýza ilustrativních případů odhalila významné rozdíly mezi hodnocením pomocí BMi a ct analýzou tělesného složení, například u případů sarkopenické obezity nebo zachované svalové hmoty, které by při použití samotného BMi zůstaly neodhaleny. Závěr: Vyvinuté uživatelské rozhraní představuje praktické řešení pro hodnocení tělesného složení u pacientů před tAVi. Systém efektivně překlenuje mezeru mezi pokročilými analytickými možnostmi validovaného softwaru AutoMAticA a klinickou praxí díky intuitivnímu uživatelskému rozhraní. toto řešení by mělo v budoucnu umožnit přesnější stratifikaci rizika a individualizovanější přístup k pacientům s indikací k TAVI.

Background: CT-derived body composition analysis has emerged as a powerful prognostic tool for TAVI patient outcomes. However, widespread clinical implementation remains limited by complex software requirements and technical expertise barriers. This study aims to develop and validate an accessible web-based interface that streamlines the implementation of existing AutoMATiCA's validated CT-based body composition assessment in the pre-TAVI evaluation workflow. Methods: We developed a web-based interface integrating the validated AutoMATiCA's AI-driven segmentation software for automated body composition assessment. The system analyses pre-procedural CT scans to quantify Skeletal Muscle Index, Visceral Adipose Tissue, and Subcutaneous Adipose Tissue. The interface accepts DICOM files and patient data, generating comprehensive reports including segmented images and measurements. Results: System evaluation demonstrated an average analysis time of 21 seconds from upload to results display. User experience assessment with five clinicians showed unanimous positive feedback regarding acces- sibility and utility. Technical validation confirmed accurate tissue segmentation and quantification capabilities. Analysis of illustrative cases demonstrated significant discrepancies between BMI-based assessment and CT-derived body composition analysis, revealing conditions such as sarcopenic obesity and preserved muscle mass that would be missed by BMI evaluation alone. Conclusion: This technical solution provides an accessible, integrated approach to body composition assessment in TAVI patients. Building upon the validated AutoMATiCA software, the system successfully bridges the gap between complex analysis capabilities and clinical practicality through an intuitive user interface. This solution should enable more precise risk stratification and a more individualized approach to patients indicated for TAVI in the future.

• MeSH
• obezita MeSH
• počítačová rentgenová tomografie metody   MeSH
• předoperační vyšetření MeSH
• sarkopenie MeSH
• složení těla * MeSH
• software MeSH
• transkatetrální implantace aortální chlopně MeSH

BACKGROUND: There are limited data on optimal management of chronic lung allograft dysfunction (CLAD). We aimed to describe the variability of diagnostic and therapeutic practices in Europe. METHODS: A structured questionnaire was sent to 71 centres in 24 countries. Questions were related to contemporary clinical practices for workup, monitoring and treatment of CLAD. The number of lung transplant procedures and patients in follow-up were collected. RESULTS: 44 centres (62%) responded from 20 countries, representing 74% of European activity. The prevalence of CLAD was estimated at 9.1 cases per million population (25th and 75th percentiles of 4.4, 15.7). Preferred initial workup for probable CLAD consisted of chest computed tomography (CT) (inspiratory 91% and expiratory 74%), donor-specific antibody (DSA) measurement (86%), bronchoalveolar lavage (BAL) (85%) and transbronchial biopsy (81%). For monitoring of definite CLAD, inspiratory CT (67%), DSA (61%) and BAL (43%) were preferred. Body plethysmography was unavailable for 16% of cases. Prophylaxis was based on preventing infections (cytomegalovirus 99%, inhaled antibiotics 70% and antifungals 65%), tacrolimus-based immunosuppression (96%), azithromycin (72%) and universal proton pump inhibitor treatment (84%). First-line treatment of CLAD was based on azithromycin (82%) and steroid augmentation (74%). Photopheresis was used in 26% of cases. CONCLUSION: Current European practice CLAD detection is based on spirometry, inspiratory CT and DSA, with limited access to plethysmography and expiratory CT. Prophylactic treatment is based on azithromycin, tacrolimus-based immunosuppression and treatment of risk factors. No single treatment strategy is universally used, highlighting the need for an effective treatment of CLAD. The preferred first-line strategy is azithromycin and steroid augmentation.

• Publikační typ
• časopisecké články MeSH

Dementia with Lewy bodies often presents with cholinergic degeneration and varying degrees of cerebrovascular disease. There is a lack of radiological methods for evaluating cholinergic degeneration in dementia with Lewy bodies. We investigated the potential of the Cholinergic Pathway Hyperintensities Scale (CHIPS) in identifying cerebrovascular disease-related disruptions in cholinergic white matter pathways, offering a practical and accessible method for assessing cholinergic integrity in neurodegenerative diseases. We assessed the associations of CHIPS with regional brain atrophy, Alzheimer's disease co-pathology and clinical phenotype. Additionally, we compared its diagnostic performance to that of other manual and automated evaluation methods. We included 82 individuals (41 patients in the Lewy body continuum with either probable dementia with Lewy bodies or mild cognitive impairment with Lewy bodies, and 41 healthy controls) from the Sant Pau Initiative on Neurodegeneration cohort. We used CHIPS to assess cholinergic white matter signal abnormalities (WMSA) on MRI, while tractography mean diffusivity provided a complementary measure of cholinergic WMSA. For global WMSA evaluation, we used the Fazekas scale and FreeSurfer. CHIPS successfully identified cerebrovascular disease-related disruptions in cholinergic white matter pathways, as evidenced by its association with tractography and global WMSA markers (P < 0.005 for all associations). Lewy body patients showed a significantly higher degree of WMSA in the external capsule cholinergic pathway despite no significant differences in global WMSA compared to controls. CHIPS score in the posterior external capsule and the mean diffusivity in the external capsule and cingulum exceeded the threshold for an optimal biomarker (sensitivity and specificity values above 80%) in discriminating Lewy body patients from controls. Furthermore, higher CHIPS scores, Fazekas scale and tractography mean diffusivity were associated with more pronounced frontal atrophy in Lewy body patients but not in controls. No associations were found for the four WMSA and integrity methods with the core clinical features, clinical or cognitive measures, or CSF biomarkers. In conclusion, cholinergic WMSA were more pronounced in Lewy body patients compared to healthy controls, independently of global WMSA. Our findings indicate that cerebrovascular disease-related disruptions in cholinergic white matter may be linked to frontal atrophy in Lewy body patients. Clinically, we demonstrate the potential of CHIPS to assess cholinergic WMSA using widely available MRI sequences. Our data suggest cerebrovascular disease co-pathology could drive the cholinergic degeneration in Lewy body patients, opening opportunities for therapeutic interventions targeting vascular health from mild cognitive impairment with Lewy bodies through manifest dementia with Lewy bodies.

• Publikační typ
• časopisecké články MeSH

INTRODUCTION: The provision of optimal care for older adults with complex chronic conditions (CCCs) poses significant challenges due to the interplay of multiple medical, pharmacological, functional and psychosocial factors. To address these challenges, the I-CARE4OLD project, funded by the EU-Horizon 2020 programme, developed an advanced clinical decision support tool-the iCARE tool-leveraging large longitudinal data from millions of home care and nursing home recipients across eight countries. The tool uses machine learning techniques applied to data from interRAI assessments, enriched with registry data, to predict health trajectories and evaluate pharmacological and non-pharmacological interventions. This study aims to pilot the iCARE tool and assess its feasibility, usability and impact on clinical decision-making among healthcare professionals. METHODS AND ANALYSIS: A minimum of 20 participants from each of the seven countries (Italy, Belgium, the Netherlands, Poland, Finland, Czechia and the USA) participated in the study. Participants were general practitioners, geriatricians and other medical specialists, nurses, physiotherapists and other healthcare providers involved in the care of older adults with CCC. The study design involved pre-surveys and post-surveys, tool testing with hypothetical patient cases and evaluations of predictions and treatment recommendations. Two pilot modalities-decision loop and non-decision loop-were implemented to assess the effect of the iCARE tool on clinical decisions. Descriptive statistics and bivariate and multivariate analysis will be conducted. All notes and text field data will be translated into English, and a thematic analysis will be performed. The pilot testing started in September 2024, and data collection ended in January 2025. At the time this protocol was submitted for publication, data collection was complete but data analysis had not yet begun. ETHICS AND DISSEMINATION: Ethical approvals were granted in each participating country before the start of the pilot. All participants gave informed consent to participate in the study. The results of the study will be published in peer-reviewed journals and disseminated during national and international scientific and professional conferences and meetings. Stakeholders will also be informed via the project website and social media, and through targeted methods such as webinars, factsheets and (feedback) workshops. The I-CARE4OLD consortium will strive to publish as much as possible open access, including analytical scripts. Databases will not become publicly available, but the data sets used and/or analysed as part of the project can be made available on reasonable request and with the permission of the I-CARE4OLD consortium.

• MeSH
• chronická nemoc terapie   MeSH
• klinické rozhodování * metody   MeSH
• lidé MeSH
• pilotní projekty MeSH
• prognóza MeSH
• senioři MeSH
• strojové učení * MeSH
• systémy pro podporu klinického rozhodování * MeSH
• Check Tag
• lidé MeSH
• senioři MeSH
• Publikační typ
• časopisecké články MeSH

Tinostamustine is a first-in-class alkylating deacetylase inhibitor that facilitates access to cancer cell DNA, resulting in its damage and counteracting DNA repair systems. We hypothesize that the addition of tinostamustine to immune checkpoint inhibitors (ICIs) improves melanoma treatment. This open-label, nonrandomized phase IB study characterized dose-limiting toxicity (DLT) and the recommended dose (RD) of 2-weekly intravenous tinostamustine at escalating doses of 15 and 30 mg/m 2 when administered with 2-weekly nivolumab 3 mg/kg added in cycle 2 in patients with melanoma. We included 17 patients (four at 15 mg/m 2 and 13 at 30 mg/m 2 tinostamustine). A total of 13/17 (77%) patients were ICI-resistant, 7/17 (41%) had unfavorable melanoma subtypes. No DLT was identified. Tinostamustine RD was 30 mg/m 2 every 2 weeks. One patient experienced grade 2 nivolumab-associated immune-related pneumonitis. Tinostamustine-associated grade 3 leukocytopenia was documented in one patient, grade 2 leukocytopenia in five patients, and grade 1 thrombocytopenia in three patients. Treatment discontinuation occurred in one patient for nivolumab-associated immune-related pneumonitis and in another patient for tumor-related hemorrhage. A total of 7/13 (54%) evaluable patients had at least stable disease as best treatment response, including 3/13 (23%) patients with a confirmed partial response. Median progression-free survival was 8.3 weeks [95% confidence interval (CI): 2.4-15.4 weeks), median overall survival was 19.1 weeks (95% CI: 2.4-41 weeks). Two-weekly intravenous tinostamustine at an immune-modulatory dose of 30 mg/m 2 is safe when coadministered with nivolumab 3 mg/kg and resulted in 54% disease stabilization and 23% confirmed partial responses in patients with predominantly ICI-resistant, advanced melanoma.

• MeSH
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• melanom * farmakoterapie   patologie   MeSH
• nádory kůže * farmakoterapie   patologie   MeSH
• nivolumab * farmakologie   terapeutické užití   aplikace a dávkování   MeSH
• protokoly protinádorové kombinované chemoterapie * terapeutické užití   farmakologie   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze I MeSH

BACKGROUND: Advanced Therapy Medicinal Products (ATMPs) represent an innovative therapeutic approach with the potential to impact the treatment of rare diseases significantly. Although authorised centrally in the European Union, their market launch differs across Member States (MS). This study aimed to describe the ATMP market availability in MS and explore potential influencing factors, providing insights into specific barriers beyond pricing and reimbursement policies. METHODS: ATMP availability was defined as the product launch in each MS. Data was collected through open governmental sources, databases, and communication with national competent authorities. Spearman's correlation coefficients were calculated to examine the relationship between ATMP availability and their characteristics (time since granting marketing authorisation, target patient population size, and cost). RESULTS: We collected the availability data on 18 ATMPs from 23 EU MS. Market uptake varied significantly, with Germany (89%), France and Italy (61%) leading. Estonia and Latvia confirmed that no ATMP has been launched on their markets yet. Six ATMPs were available in more than one-third of the analysed MS. No significant correlation was observed between ATMP availability and analysed product characteristics except for time dependency for CAR T-cell therapies. CONCLUSION: Beyond pricing and reimbursement processes, the ATMP commercialisation in particular MS is influenced by the marketing authorisation holder's decision and capacity. ATMPs face product-specific challenges in achieving EU-wide availability, including complex manufacturing, distribution, and administration processes. To increase the accessibility of innovative ATMP-based treatments, implementing the cross-border access framework or individual ATMP production under the hospital exemption is essential, especially in underserved MS.

• MeSH
• dávkové mechanismy * MeSH
• Evropská unie MeSH
• vzácné nemoci terapie   MeSH
• Publikační typ
• časopisecké články MeSH

Celotělovápostmortem CTangiografie(PMCTA) představujevcelosvětovémměřítkuexperimentálnímetoduzávisloupředevšímnadostupnostiinterdisciplinární spolupráce, personálním a technickém vybavení a finančních možnostech pracoviště. Autoři prezentují technické poznámky k etablovaní PMCTA na pracovišti, které od roku 2015 rutinně provádělo nativní CT vyšetření. Aplikaci této diagnosticky i vědecko-výzkumně výtěžné metody do soudnělékařské praxe umožnila mezioborová spolupráce společně s institucionální podporou rozvoje nových diagnostických metod.

Whole-body post mortem CT angiography (PMCTA) is an innovative and experimental imaging technique that relies heavily on interdisciplinary collaboration, access to skilled personnel, advanced technical equipment and the financial possibilities of the workplace. Native CT examinations (PMCT) prior to autopsy are already a standard procedure in certain forensic departments in the Czech Republic (e.g., murders, suicides, deaths of children, traffic accidents etc.). Nonetheless, the progression of forensic sciences all over the world shows the necessity to integrate other advanced imaging modalities in routine forensic practice. Incorporating PMCTA into standard forensic workflows enhances the precision of forensic diagnostics, supplements traditional autopsy findings, and elevates the objectivity of forensic outputs. This paper presents technical notes on the development of PMCTA in forensic practice in a department that since 2015 until now has routinely performed native CT examinations. Institutional support was crucial in enabling the adoption of the imaging technique, which has so far been applied to more than thirty cases. The department is currently conducting a comparative study focused on the application of three different types of perfusion media – polyethylene glycol (PEG), saline, paraffin oil – and assessing the diagnostic efficacy of PMCTA relative to conventional autopsy. Based on our experience, PMCTA is suitable for all corpses except those with advanced post-mortem decomposition or extensive open injuries. The highest diagnostic yield is achieved in cases involving suspected gastrointestinal bleeding or vascular pathologies and lesions especially of large vessels (e.g., dissection/rupture of the aorta). The protocol for whole-body PMCTA can be adapted to meet the specific needs and conditions of individual forensic departments, providing a flexible yet robust framework for enhancing forensic medical investigations.

• MeSH
• CT angiografie metody   MeSH
• diagnostické zobrazování metody   MeSH
• lidé MeSH
• pitva * metody   MeSH
• počítačová rentgenová tomografie * metody   MeSH
• soudní lékařství metody   trendy   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• práce podpořená grantem MeSH

Využití digitální patologie a umělé inteligence v anatomické patologii představuje revoluční krok směrem k modernizaci diagnostických procesů. Digitalizace, postavená zejména na využívání tzv. whole slide imaging, umožňuje vytvářet celoplošné digitální obrazy histologických preparátů, což přináší potenciální benefity v oblasti přesnosti a dostupnosti diagnostiky. Na rozdíl od tradiční mikroskopie poskytuje digitální patologie též možnost telemedicíny a vzdálené konzultace, čímž otevírá nové možnosti spolupráce a sdílení odborných znalostí na národní i mezinárodní úrovni. Implementace digitálního pracovního postupu nicméně vyžaduje rozsáhlé investice do skenerů, softwarových platforem, vysokokapacitních úložišť a IT infrastruktury. Navzdory nemalým nákladům na implementaci však přináší řadu výhod, včetně časových úspor, možnosti centralizace diagnostiky a snížení nákladů na transport vzorků. Tento příspěvek se zaměřuje na praktické aspekty implementace digitální patologie v patologických laboratořích s důrazem na přínosy, rizika a technologické požadavky spojené s digitalizací a diskutuje i zásadní role validace a verifikace celého nového pracovního procesu. Článek představuje digitální patologii jako dynamicky se rozvíjející obor s vysokým potenciálem pro personalizovanou medicínu, zlepšení diagnostické přesnosti a podporu vzdálené spolupráce, čímž reaguje na rostoucí nároky moderní medicíny.

The application of digital pathology and artificial intelligence in anatomical pathology represents a revolutionary step towards the modernization of diagnostic processes. Digitalization, primarily based on creation and subsequent use of whole slide imaging, enables generating of full digital images of histological slides, offering potential benefits in diagnostic accuracy and accessibility. Unlike traditional microscopy, digital pathology also facilitates telemedicine and remote consultation, opening new possibilities for collaboration and sharing of expertise at both national and international levels. However, implementing a digital workflow requires substantial investments in scanners, software platforms, high-capacity storage, and IT infrastructure. Despite considerable costs of implementation, it brings numerous advantages, including time savings, opportunities for centralized diagnostics, and a reduction in sample transport costs. This paper focuses on the practical aspects of implementing digital pathology in pathology laboratories, emphasizing the benefits, risks, and technological requirements associated with digitalized workflows. It also discusses crucial roles of validation and verification, which are essential for ensuring a diagnostic accuracy of digital images compared to conventional microscopy. The article presents digital pathology as a dynamically evolving field with high potential for personalized medicine, improved diagnostic accuracy, and support for remote collaboration, addressing the growing demands of modern medicine.

• MeSH
• lidé MeSH
• patologie * trendy   MeSH
• strojové učení * trendy   MeSH
• telemedicína trendy   MeSH
• Check Tag
• lidé MeSH